For instance, immune checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 antibodies show limited efficacy in GBM, partly because they fail to accumulate in sufficient concentrations at the tumor site due to the BBB (Pol et al., 2024). Here, CTLA4 is linked to glioblastoma.